In the article “Adverse effects of systemic cancer therapy on skeletal muscle: myotoxicity comes out of the closet” [1], an incorrect article was discussed in the text, rather than the one cited. Please find a corrected paragraph below discussing the referenced paper.

This would replace what is currently the last paragraph under the sub-heading “MOLECULAR PATHWAYS OF SYSTEMIC TREATMENT-RELATED MUSCLE LOSS”:

Although it will be important to assess which of the mechanisms described in experimental systems are at play in patients with cancer, human studies characterizing effects of systemic cancer therapy at the tissue level are challenging, owing to the invasive nature of muscle biopsy. Mallard et al [49▪▪] conducted serial biopsy of the vastus lateralis muscle before, and after a 24-week course of epirubicin-cyclophosphamide regimen followed by weekly paclitaxel for early-stage breast cancer. This serial biopsy approach allowed the investigators to record changes in mitochondrial biogenesis, mitochondrial dynamics and mitophagy [49▪▪] as well as fatty infiltration [50], specific to a treatment plan that includes anthracycline, cyclophosphamide and taxane. Although muscle mass loss was undetectable by CT when patients received this regimen [12,13▪,14] (see above), microscopic and biochemical tests reveal important changes.

The original annotation for reference 49 should also be disregarded, and instead corrected to the following:

▪▪ Only available human study with repeated muscle biopsy before and after chemotherapy.

1. Klassen, Pamela; Schiessel, Dalton L.; Baracos, Vickie E. Adverse effects of systemic cancer therapy on skeletal muscle: myotoxicity comes out of the closet. Current Opinion in Clinical Nutrition and Metabolic Care 26(3):p 210-218, May 2023.